TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00027846

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given IV or SC (5mcg/kg/day) start on Day 3 and continue until ANC \>1500/μl given subcutaneously or intravenously.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: carboplatin
Description: Given IV (375 mg/m2/day) Day 1 given as an IV infusion over one hour. For patients with BSA \<0.45m2 the dose is 12.5 mg/kg/day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV (1000mg/m2/day) Day 1 and 2 given as an IV infusion over one hour following carboplatin administration. For patients with BSA\<0.45m2 the dose is 33mg/kg/day on Day 1 and 2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given orally (50 mg/m2/day) orally once daily on Days 1 through 21. For patients with BSA \< 0.45 m2, the dosage is 1.7 mg/kg/day on Days 1 through 21.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Description: Given IV or orally (1.5mg/m2/day) (maximum dose 2 mg) Day 1 and 8 given as IV bolus. For patients with BSA\<0.45m2 the dose is 0.05mg/kg.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given once daily 5 days a week for 6-6½ weeks

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: Given once daily 5 days a week for 6-6½ weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mesna
Description: Mesna (200mg/m2/dose) Day 1 and 2. For patients with BSA\<0.45m2 the dose is (7mg/kg/dose). Combine mesna (200mg/m2) with cyclophosphamide and administer intravenously over one hour followed by mesna (200mg/m2) in 375 cc/m2 D5-1/2NS and run intravenously over 3 hours at 125cc/m2/hr. After 3 hour mesna, administer mesna (200 mg/m2/dose) IV over 15 minutes at hour 5.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: therapeutic conventional surgery
Study: NCT01473108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY 94-8862) PEG solution
Description: 2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY 94-8862) PEG solution
Description: 2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY 94-8862) PEG solution
Description: 2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY 94-8862) PEG solution
Description: 2.5, 5, 10, 20 mg polyethylene glycol (PEG) solution of BAY 94-8862

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Finerenone (BAY 94-8862) immediate release tablet
Description: 20 mg BAY 94-8862 administered as 2 x 10 mg IR tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Inspra®)
Description: Single oral dose of 50 mg eplerenone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Inspra®)
Description: Single oral dose of 50 mg eplerenone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Inspra®)
Description: Single oral dose of 50 mg eplerenone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Inspra®)
Description: Single oral dose of 50 mg eplerenone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eplerenone (Inspra®)
Description: Single oral dose of 50 mg eplerenone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo (solution/tablet) corresponding to BAY 94-8862 dose in respective dose step
Study: NCT04135300

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Single dose intravenous injection of BBM-H901
Description: Single dose intravenous infusion of BBM-H901, an adeno-associated viral (AAV) vector designed to drive expression of the human factor IX (hFIX) transgene in liver. The dose of BBM-H901 will be 5x10'12 vg/Kg.
Study: NCT03473821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOTIFS
Description: o MOTor Imagery to Facilitate Sensorimotor re-learning (MOTIFS) is an individualized and physical activity-specific integrated model that includes aspects of both neuromuscular training, as used in rehabilitation practices, and Dynamic Motor Imagery (DMI). DMI is a form of mental training in which the participant images him-/herself performing a task from a first-person perspective in order to maximize functional equivalence to the task in question. This includes dynamic, physical movement, as well as mental imaging. The intervention provides a framework for designing individualized, physical activity-specific rehabilitation exercises for knee-injured people.
Study: NCT03809260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (part 1)
Description: 1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch), 16d\~19d: Metformin 1000 mg bid (Except for 500 mg after 16d lunch).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: 11d: Vancomycin 250 mg bid, 12\~17d: Vancomycin 500 mg bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin (part 2)
Description: 1\~4d: Metformin 1000 mg bid (Except for 500 mg after 1d lunch)
Study: NCT02384096

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional single source programming
Description: Precision Spectra SCS System using conventional single source programming.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional single source programming
Description: Precision Spectra SCS System using conventional single source programming.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision Spectra SCS System advanced programming
Description: Precision Spectra SCS System using advanced programming

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Precision Spectra SCS System advanced programming
Description: Precision Spectra SCS System using advanced programming
Study: NCT06254794

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Blood flow restriction with Delfi Personalized Tourniquet System (PTS)
Description: Standard of care physical therapy exercises with the use of the Delfi PTS cuff

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical therapy
Description: Standard of care physical therapy exercises

Intervention type: OTHER
Group type: OTHER
Intervention: Physical therapy
Description: Standard of care physical therapy exercises
Study: NCT04297111

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic
Description: GanedenBC30 (Bacillus coagulans GBI-30, 6086) capsule made of 1 billion colony forming units (cfu). Description: pure cell mass of an L-(+) lactic acid-producing, gram-positive, spore-forming shaped bacterium that is aerobic to microaerophilic. Maltodextrin used as filler.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Maltodextrin capsule, no active ingredient
Study: NCT05102773

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood and stool

Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo CT

Intervention type: OTHER
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaire
Study: NCT05109949

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10Mg Tab
Description: Daily morning dose per oral of Dapagliflozin 10 mg for 7 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 MG
Description: Daily morning dose per oral of Empagliflozine 25 mg for 7 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily morning dose per oral of Calcined magnesite 500 mg for 7 days
Study: NCT00821847

Intervention type: OTHER
Intervention: DEXA scan
Description: DEXA scan
Study: NCT04095611

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SPAIRE
Description: To perform the hip surgery called hemiarthroplasty surgeons need to cut through some muscles to expose the hip joint and perform the partial replacement. Currently this often performed using a technique which involves cutting muscles and tendons from the side of the hip and this is called the lateral approach. SPAIRE is a modified technique that accesses the surgical area through a different route.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LATERAL
Description: surgery in adults with a displaced intracapsular hip fracture requiring hemiarthroplasty, the standard lateral approach.
Study: NCT03759002

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness

Intervention type: DIAGNOSTIC_TEST
Intervention: Imaging
Description: Imaging including Echocardiography for determining cardiac indices (ejection fraction, left ventricular mass index, strain rate, global longitudinal strain) and Doppler ultrasound for measuring carotid intima media thickness
Study: NCT04221165

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAiN - multimodal analgesia
Description: PAiN: Pregabalin, Acetaminophen, Naproxen, pantoprazole magnesium
Study: NCT03759002

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling will performed on all participants for measuring hematological parameters including MPV.

Intervention type: OTHER
Intervention: Blood sampling
Description: Blood sampling will performed on all participants for measuring hematological parameters including MPV.
Study: NCT03606018

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin Lispro Mix 25
Description: insulin lispro biphasic in doses 0.4 ME/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog® Mix 25
Description: insulin lispro biphasic in doses 0.4 ME/kg
Study: NCT02285699

Intervention type: DRUG
Group type: OTHER
Intervention: SSRIs
Description: 12-weeks of standard SSRi treatment for those interested in Phase II of the study.
Study: NCT03970330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone
Description: 4.5mg daily dose, taken orally
Study: NCT03883178

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimal-invasive endoscopic transgluteal approach
Description: Every patient, suffering from a pudendopathie or clunealgie, conform the Nantes criteria, and who are candidates for a surgical treatment through the transgluteal open approach, will be asked their permission to perform the procedure through a minimal-invasive endoscopic transgluteal approach.
Study: NCT04265872

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib; pembrolizumab and cisplatin injections--bortezomib followed by pembro/cis
Description: injection into a vein
Study: NCT01441336

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic gastrectomy
Description: Operative procedure: laparoscopic gastrectomy(D2 lymphadenectomy according to JGCA guideline and total omentectomy for tumor with serosa exposure)
Study: NCT02782000

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lessons,long-term supervision and message

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lessons,short-term supervision and message
Study: NCT03970330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone Acetate
Description: 5 - 15mg daily dose, taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Norethindrone Acetate
Description: 5 - 15mg daily dose, taken orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: daily placebo pill, taken orally
Study: NCT04220502

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magic Shave Powder Gold
Description: Depilatory Cream for facial hair removal

Intervention type: DEVICE
Group type: OTHER
Intervention: Traditional Shaving Methods
Description: Continued facial hair removal using traditional razors
Study: NCT04058782

Intervention type: OTHER
Intervention: Imaging evaluation for vascular assessment
Description: At 1month after MI, Blood sample for total blood, plasma and PBMC collection, ECG, 3D-trans thoracic echocardiography for ventriculo-arterial coupling assessment, Vascular doppler for peripheral artery disease assessment, Arterial stiffness evaluation, Bilateral transcranial doppler for HITS evaluation
Study: NCT03527875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PTBD group
Description: Percutaneous Transhepatic Biliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ENBD group
Description: Endoscopic Nasobiliary Drainage, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
Study: NCT00911300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: unfractionated heparin
Description: Comparison of different drugs
Study: NCT03556267

Intervention type: DEVICE
Group type: OTHER
Intervention: spinal needle
Description: It is a spinal needle with 'QUINCKE' Bevel. It is inserted in the lumbar region at the inter-space L4-L5, L4-L3 ,or L3-L2 lumber spaces, while the patient is put in the sitting position then CSF sample is taken then 2.5 ml of a local anesthetic(0.5 ml of 25 ug fentanyl and 2 ml of 8 mg heavy bupivacaine) is given intrathecal then the needle is withdrawn.
Study: NCT03527875

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBS group
Description: Endoscopic Biliary Stenting, a kind of Preoperative Biliary Drainage methods for hilar cholangiocarcinoma patients
Study: NCT01652651

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: I Can Succeed ICS
Description: ICS is a manual-based psychological intervention aimed to address both emotional and academic-executive functions aspects of LD.It consists of acute phase (13 once a week sessions) and follow-up phase (6 sessions over 18 months). ICS focuses on developing intrapersonal skills (e.g. self awareness, goal setting, organizational skills), interpersonal skills (e.g. communication, problem solving)and school/community skills (i.e. strengthening the family-school relationship) (Kopelman-Rubin et al., 2011).
Study: NCT02547974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation 1 (plain): NTHi/Mcat vaccine GSK3277513A
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
Study: NCT02828098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 1: BO-112
Description: Cohorts of three patients per dose level will be treated consecutively in the absence of Dose Limiting Toxicity (DLT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Part 2: BO-112
Description: BO-112 at a fixed dose will be administered as an intratumoral injection for up to 5 doses over 12 weeks and continue as long as there is benefit.~Nivolumab will be administered as an intravenous infusion every 2 weeks at a dose of 3 mg/kg for up to a total period of one year.~OR Pembrolizumab will be administered as an intravenous infusion every 3 weeks at either 200 mg or at 2 mg/kg depending on the indication, for up to a total period of one year.
Study: NCT02094066

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tranexamic acid
Description: preoperative ıv 50 mg/kg tranexamic acid infusion at 45 minutes

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: serum physiologic
Description: preoperative 100 cc ıv serum physiologic
Study: NCT04184674

Intervention type: OTHER
Group type: OTHER
Intervention: Pneumotachograph
Description: Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures).

Intervention type: OTHER
Group type: OTHER
Intervention: Esophageal catheter
Description: Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures).

Intervention type: OTHER
Group type: OTHER
Intervention: Transthoracic and / or transesophageal cardiac ultrasound
Description: The right ventricle systolic function will be assessed thanks to a transthoracic cardiac ultrasound in children, and a transthoracic of a transesophageal cardiac ultrasound in adults :~Measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management :~* The first measurement will be performed 5 minutes after the initial ventilator settings.~* Measurements will be repeated systematically at 24 hours, 48 hours and 72 hours of evolution.~* An additional measure will be performed at each positive end-expiratory pressure modification (maximum 5 measures).

Intervention type: OTHER
Group type: OTHER
Intervention: Electrical impedance tomography (EIT) for pediatric patients
Description: For pediatric patients: measurements will be performed during the first three days of Acute Respiratory Distress Syndrome management.
Study: NCT04987684

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SCINSEV and PECAP
Description: To measure PECAP and SCINSEVs. To find whether electrodes are outside of the cochlear or within dead regions within the cochlear.
Study: NCT02547974

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation 2 (adjuvanted): NTHi/Mcat vaccine GSK3277513A
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Formulation 3 (adjuvanted): NTHi/Mcat vaccine GSK3339036A
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 doses at Day 0 and Day 60, Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule
Study: NCT04599543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IL3 CAR T-cells
Description: Each subject receive IL3 CAR T-cells by intravenous infusion
Study: NCT02511691

Intervention type: DRUG
Group type: OTHER
Intervention: 18F-PSS232
Description: Diagnostic PET Tracer
Study: NCT01200251

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bimatoprost eyelash gel
Description: Bimatoprost 0.03% solution was compounded into a gel - patients used on eyelash margin once daily placing gel with a fingertip or Q-tip for 6 months
Study: NCT02390167

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ONYX NEXT BGMS
Description: Untrained Persons WITH Diabetes Use the ONYX NEXT BGMS (Blood Glucose Monitoring System). Subjects tested capillary fingerstick and palm blood (and study staff tested subject fingerstick blood) using the ONYX NEXT BGMS. All BG results were compared to reference method results obtained with subject capillary plasma. Also, study staff tested venous blood from subjects WITH Diabetes and BG results were compared to reference method results obtained from the subjects' venous plasma.
Study: NCT00911300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin-K-Antagonist
Description: Comparison of different drugs
Study: NCT04447560

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Erector Spinae Plane Block
Description: One researcher will record the artery images as explained in the protocol and two researchers will measure the radius and area of those vessels separately. Researchers who are measuring the radius and area of vessels won't know whether those images belong to pre or post- ESP block. The results two researchers measure will be compared statistically and if there are no statistically significant differences, the mean value of their separate recordings will be taken into account for the statistical analysis.
Study: NCT00248872

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention Group
Description: During the physical activity goal setting process, subjects were randomly assigned to either the control or the intervention group. The intervention included receiving an additional educational workbook about using positive affect and self affirmation, as well as participating in using positive affect and self-affirmation to motivate behavior change, which in this case was to increase their medication adherence. Patient also received small token gifts to remind them of their participation in the study and to induce positive affect. The control group also set a physical activity goal and received the same follow-up, but did not participate in the positive affect and self-affirmation portion.